Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

After <a href="https://www.londonstockexchange.com/exchange/news/alliance-news/detail/1530796098973581400.html" target="_blank">confirmation of discussions</a> of the merger back in early July, <a href="https://www.smartkarma.com/entities/23385" target="_blank" data-smartkarma-citation="entities:23385:1">Sinclair Pharma (SPH LN)</a> announced it has entered into an <a href="https://www.sinclairpharma.com/wp/wp-content/uploads/2018/08/Possible_Offer_Announcement-dated_28_August_2018.pdf" target="_blank">Offer Agreement</a> with <a href="https://www.smartkarma.com/entities/18522" target="_blank" data-smartkarma-citation="entities:18522:1">Huadong Medicine Co Ltd A (000963 CH)</a>.
A Possible Offer, should it occur, is expected to be at £0.32/share for all of Sinclair’s issued shares, valuing the company at £161.2mn. Huadong is expected to announce a firm offer on or before 5 October 2018, provided the pre-conditions are satisfied or waived.  Sinclair's Independent Directors are of the view that the Possible Offer is an attractive proposal.

After confirmation of discussions of the merger back in early July, Sinclair Pharma (SPH LN) announced it has entered into an Offer Agreement with Huadong Medicine Co Ltd A (000963 CH).
A Possible Offer, should it occur, is expected to be at £0.32/share for all of Sinclair’s issued shares, valuing the company at £161.2mn. Huadong is expected to announce a firm offer on or before 5 October 2018, provided the pre-conditions are satisfied or waived.  Sinclair's Independent Directors are of the view that the Possible Offer is an attractive proposal.

China Grand Pharmaceutical and Healthcare (512 HK)

China Grand Pharmaceutical and Healthcare

Europe M&A: Huadong's Offer for Sinclair Looks a Done Deal